Session: SUN 554-573-Ovarian & Uterine Function I
Poster Board SUN-562
Aim: To compare the use of ADM in patients with PCOS vs. controls.
Methods: The study was a register based study covering the residents of the Danish County of Funen linking data from Odense Pharmacoepidemiologic Database (OPED) and Funen Patient Administrative System (FPAS), a database with data on all secondary care contacts. 1124 premenopausal women referred to our outpatient clinic during 1997 –2012 with hirsutism and/or PCOS were included (first entry at department = index date). Two control groups were established: women from the outpatient hypertensive clinic (HT, n=301) and age-matched women from the population of Funen obtained by risk-set sampling of up to four controls per case (controls, n=4110). Using OPED, prescriptions for ADM were extracted for all subjects. Time to first treatment with ADM after cohort entry was analysed by Cox-regression. The analyses were adjusted for potential confounders present at cohort entry and age (HT only).
Results: The median age at cohort entry in PCOS, HT and controls was 29, 34 and 29 years, respectively. Among PCOS, HT and controls, 227 (20%), 74 (25%) and 633 (15%) respectively had prescriptions of ADM. The median time to first use of ADM in the PCOS, HT and control cohorts was 6.8, 6.6, and 7.2 years respectively. The adjusted hazard ratio for time to prescription of ADM for PCOS vs. HT was 1.36 (95% CI [1.02 to 1.82]), p=0.039, and for PCOS vs. controls it was 0.75 (95% CI [0.64 to 0.88], p<0.001.
Conclusion: Patients with PCOS had decreased time to first prescription of ADM compared to age matched healthy women, whereas women with hypertension had shorter time to first prescription of ADM than women with PCOS.
Nothing to Disclose: DG, MA, RDC, JH, MA
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters